Meta-analysis of statins in chronic kidney disease: Who benefits?
QJM: An International Journal of Medicine — Messow CM, et al. | March 20, 2017
Analysts decide the extent to which the adequacy of statins varies by kidney class. Statins are shown in stage 3 chronic kidney disease (CKD), probably demonstrated in CKD4, not showed in CKD5/5D and probably showed in patients with a functioning transplant. Too few patients with CKD4 and renal transplants have been included in lipid lowering trials for confident conclusions to be drawn.